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Caseinolytic peptidase P (ClpP), a double-ring peptidase with 14
subunits, collaborates with ATPases associated with diverse activi-
ties (AAA+) partners to execute ATP-dependent protein degrada-
tion. Although many ClpP enzymes self-assemble into catalytically
active homo-tetradecamers able to cleave small peptides, theMyco-
bacterium tuberculosis enzyme consists of discrete ClpP1 and ClpP2
heptamers that require a AAA+ partner and protein–substrate de-
livery or a peptide agonist to stabilize assembly of the active tetra-
decamer. Here, we show that cyclic acyldepsipeptides (ADEPs)
and agonist peptides synergistically activate ClpP1P2 by mimicking
AAA+ partners and substrates, respectively, and determine the
structure of the activated complex. Our studies establish the basis
of heteromeric ClpP1P2 assembly and function, reveal tight cou-
pling between the conformations of each ring, show that ADEPs
bind only to one ring but appear to open the axial pores of both
rings, provide a foundation for rational drug development, and
suggest strategies for studying the roles of individual ClpP1 and
ClpP2 rings in Clp-family proteolysis.
AAA+ proteases | allosteric coupling | pathogen drug target
The self-compartmentalized caseinolytic peptidase P (ClpP)functions in collaboration with the ATPases associated with
diverse activities (AAA+) ClpX, ClpA, or ClpC enzymes to carry
out ATP-dependent proteolysis in bacteria and eukaryotic or-
ganelles (1). The physiological importance of these proteolytic com-
plexes is reflected in their requirement for the viability and/or
virulence of some bacteria and the observation that loss-of-func-
tion mutations in mammals are linked to developmental defects
and disease (2–8). Most well-characterized ClpP enzymes come
from organisms that have a single clpP gene and consist of identical
heptameric rings, which stack face-to-face to enclose a degradation
chamber in which 14 active sites mediate peptide-bond hydrolysis
(1, 9, 10). Importantly, the proteolytic chamber is accessible only
via narrow axial pores that allow entry of small peptides, greatly
slow entry of larger peptides or unfolded proteins, and block access
of native proteins (11, 12). Degradation of proteins is mediated by
the ClpXP, ClpAP, or ClpCP proteolytic complexes. In these
enzymes, the AAA+ partner forms a ring hexamer that binds
peptide degrons in target proteins, unfolds native structure if
necessary, and translocates the unfolded polypeptide through
a central channel and into the lumen of ClpP for degradation (13).
When AAA+ partner proteins bind to ClpP, one consequence
is opening of the narrow axial pores (12, 14, 15). Binding is
mediated in part by tripeptide motifs [typically Ile-Gly-Phe or
Leu-Gly-Phe (LGF)] in flexible loops in the AAA+ hexamer,
which dock into hydrophobic pockets at subunit interfaces on each
ClpP heptamer (16–19). In a remarkable example of protein
mimicry by a natural product, cyclic acyldepsipeptide (ADEP)
antibiotics bind in the same hydrophobic pockets on ClpP and also
open the axial pores, potentially leading to unregulated protein
degradation and cell death (14, 15, 20, 21).
In contrast to organisms with one ClpP, two or more ClpP iso-
forms are characteristic of two large bacterial phyla (Actinobacteria
and Cyanobacteria) and also occur in individual species from other
phyla (22, 23). For example, Mycobacterium tuberculosis, a path-
ogenic actinobacterium, encodes cotranscribed clpP1 and clpP2
genes (24, 25). The importance of Clp-family proteolysis in
M. tuberculosis is highlighted by the facts that the clpP1, clpP2,
clpX, and clpC1 genes are all essential and that mechanism-based
ClpP inhibitors suppress growth (24, 26–28). Recent studies in-
dicate that M. tuberculosis ClpP1 and ClpP2 form discrete hep-
tameric rings that assemble into an active ClpP1P2 tetradecamer
only in the presence of a ClpX or ClpC1 AAA+ partner and one
additional factor, either protein substrates being actively trans-
located into the degradation chamber or N-blocked peptide ago-
nists (23, 29). Because M. tuberculosis resistance to conventional
antibacterial drugs is a major health hazard, there is substantial
interest in developing drugs that target ClpP1P2. At the outset of
this work, however, there was no structure of M. tuberculosis
ClpP1P2 or any heteromeric ClpP enzyme to guide design efforts.
Here, we show that a catalytically active ClpP1P2 tetradecamer
can be stabilized by the combination of a novel ADEP and an
agonist peptide, which allowed crystallization and determination of
the 3D structure. Together, our structural and biochemical results
reveal the basis for ClpP1P2 assembly and activation, establish that
the conformations of the ClpP1 and ClpP2 rings are tightly cou-
pled, show that ADEPs bind exclusively to one ring, and suggest
strategies for the design of active ClpP1 orClpP2 tetradecamers for
studies of AAA+ partner specificity and biological function.
Significance
Caseinolytic peptidase P (ClpP) normally collaborates with
ATPases associated with diverse activities (AAA+) partner
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Mycobacterium tuberculosis is required for survival of this
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binding of protein substrates and small molecules that mimic
binding of a AAA+ partner and cause unregulated rogue pro-
teolysis. These studies explain why two different ClpP rings are
required for peptidase activity and provide a foundation for
the rational development of drugs that target ClpP1P2 and kill
M. tuberculosis.
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Results
ADEPs Activate M. tuberculosis ClpP1P2 and Block ClpX Binding in
Vitro. ADEPs bind to many homomeric ClpP enzymes and acti-
vate cleavage of large peptides and unstructured proteins (20, 21).
They also inhibit M. tuberculosis growth in the presence of efflux-
pump inhibitors (30), strongly suggesting that ClpP1P2 also should
be an ADEP target, with toxicity resulting either from activation of
rogue degradation and/or from inhibition of interaction with a
AAA+ partner. To test for activation, we assayed ClpP1P2 cleavage
of a decapeptide in the presence of known and novel ADEP ana-
logs having macrocycles of differing rigidity and either straight or
branched acyl side chains (Fig. 1A) (30, 31). We found that
ClpP1P2 was activated in the presence of both an ADEP and a
peptide agonist [in this experiment carboxybenzyl-leucine-leucine-
norvaline-aldehyde (Z-Leu-Leu-Nva-CHO)], a combination that
did not activate cleavage by ClpP1 alone or ClpP2 alone (Fig. 1B).
In titration studies, ClpP1P2 activation displayed positive coopera-
tivity with half-maximal ADEP stimulatory concentrations from ∼5
to >250 μM depending on the molecule (Fig. 1C and Table S1).
The tighter-binding ADEPs had a more rigid macrocycle, as an-
ticipated from previous ClpP-activation studies (30, 31). Methyl
branching on the acyl side chain was important also. Indeed,
ADEP-2B5Me and ADEP-2B6Me, two of the tightest binders, had
acyl side chains reminiscent of Ile and Leu, which are the most
common residues at the first position of the AAA+ tripeptide-
docking motif (16). The ADEPs tested also had a difluor-
ophenylalanine that mimics the last residue in the tripeptide
motif (15), which is LGF in M. tuberculosis ClpX and ClpC1.
To assess how different combinations of ADEP and a Z-Ile-
Leu agonist peptide affected the reactivity of the peptidase active
sites, we used a fluorescent reagent, tetramethylrhodamine
(TAMRA)-fluorophosphonate, that modifies active-site serines
and a ClpP1P2 variant in which ClpP1 was fused to a C-terminal
small ubiquitin-related modifier (SUMO) domain to allow sepa-
ration from ClpP2 by SDS/PAGE. Following incubation for dif-
ferent time periods, samples were run on a gel, and active-site
reactivity was assessed by fluorescence (Fig. 1D). In these experi-
ments, ADEP-2B alone increased the rate of active-site modifi-
cation of ClpP2 modestly, Z-Ile-Leu alone had little effect on
active-site reactivity, but the combination of ADEP-2B and Z-Ile-
Leu increased the rate of modification of both ClpP1 and ClpP2
substantially. These results in combination with the activation
results described above indicate that ADEPs and agonist peptides
bind to an enzymatically active conformation of ClpP1P2 and, in
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Fig. 1. ADEPs activate M. tuberculosis ClpP1P2 in vitro. (A) Chemical structures of ADEPs used in this study. The syntheses of ADEP-1A, ADEP-1B_cyc,
ADEP-1C_cyc (IRD-10011), and ADEP-2B have been described (30, 31, 37). The synthesis of ADEP-2B5Me and ADEP-2B6Me are described in SI Methods. (B)
Cleavage of a fluorogenic decapeptide (15 μM) by ClpP1 alone (0.25 μM), ClpP2 alone (0.25 μM), or ClpP1 and ClpP2 (0.25 μM each) was assayed in the absence
or presence of Z-Leu-Leu-Nva-CHO agonist (50 μM) and/or ADEP-2B (20 μM). Robust peptidase activity required ClpP1, ClpP2, agonist, and ADEP. (C) Cleavage
of the decapeptide peptide substrate (15 μM) by ClpP1P2 (0.25 μM) was assayed in the presence of increasing concentrations of different ADEPs and Z-Leu-
Leu-Nva-CHO agonist (50 μM). Values are averages ± SD (n = 3); many error bars are smaller than the plot symbols. Data were fit to a Hill equation (fitted
parameters are listed in Table S1). (D) A complex consisting of ClpP1SUMO and ClpP2 (0.25 μM each) was incubated with TAMRA-fluorophosphonate (2 μM) for
different times in the absence or presence of Z-Ile-Leu peptide (0.5 mM) and/or ADEP-2B (50 μM). Samples were denatured and electrophoresed on SDS gels, and
TAMRA fluorescence was detected using a fluorescence imager. (E) Increasing concentrations of ADEP-2B inhibited degradation of GFP-ssrA (10 μM) by ClpX
(0.5 μM) and ClpP1P2 (2 μM). Values are averages ± SD (n = 3). The line is a fit to a Hill equation; fitted parameters are listed in Table S2.
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combination, stabilize this structure to a far greater extent than
either single ligand alone.
To test the possibility that ADEPs could be toxic because they
prevent binding of a AAA+ partner to ClpP1P2, we assayed
degradation of a degron-tagged protein substrate (GFP-ssrA) by
M. tuberculosis ClpX and ClpP1P2 in the presence of increasing
concentrations of ADEP-2B (Fig. 1E). Strikingly, complete in-
hibition of GFP-ssrA degradation was observed at high ADEP
concentrations, supporting a model in which ADEP binding to
ClpP1P2 blocks ClpX binding. These results also show that
ADEP-activated ClpP1P2 cannot degrade the natively folded
protein substrate used in this experiment.
Crystal Structures. Crystals grew over the course of ∼9 mo in
drops containing selenomethionine-labeled ClpP1, native ClpP2,
ADEP-2B5Me, and a Z-Ile-Leu agonist peptide. Diffraction data
to ∼3.2-Å resolution were collected on two crystals with different
morphologies from a single crystallization drop, and the struc-
tures were solved bymolecular replacement (Table 1). One crystal
form had two ClpP1P2 tetradecamers in the asymmetric unit.
Despite the modest resolution, the use of noncrystallographic
symmetry during refinement (14 copies of each chain in the
asymmetric unit) resulted in clear electron-density maps (Fig. 2A
and Fig. S1), R and Rfree values of ∼0.19 and ∼0.22, respectively,
and good model geometry (Table 1). Both the distribution of
selenium sites in an anomalous map from the initial molecular
replacement solution (Fig. S2) and structural refinement
established that each tetradecamer consisted of one heptameric
ring of selenomethionine-labeled ClpP1 and one heptameric ring
of unlabeled ClpP2 (Fig. 2B). The two ClpP1P2 tetradecamers in
the asymmetric unit had similar structures. The individual hepta-
meric ClpP1 and ClpP2 rings in ClpP1P2 had similar overall con-
formations, with an rmsd of 0.72 Å for common main-chain atoms.
The equatorial interface between the ClpP1 and ClpP2 rings was
well ordered (Fig. 2A), and the heteromeric complex adopted an
extended conformation (∼93 Å high; ∼96 Å across; Fig. 2 B–D),
similar to the active conformations of homomeric tetrade-
camers of other bacterial ClpP peptidases (1). The second crystal
contained a ClpP1P1 tetradecamer (Fig. 2 E and F), which was
shorter and wider than the ClpP1P2 tetradecamer (Fig. 2 B and E)
and was nearly identical to a previous structure (32) with respect
to all-atom rmsd (0.32 Å), space group, and unit-cell dimensions
(Table 1).
In the ClpP1P2 tetradecamer, ADEP-2B5Me molecules were
bound exclusively in the LGF-binding pockets of ClpP2, whereas
Z-Ile-Leu agonist peptides were bound within all 14 active sites
(Fig. 2 B–D). Although the ClpP1P1 crystals grew in the pres-
ence of ADEP-2B5Me and Z-Ile-Leu, neither ligand was bound in
the structure. In the ClpP1P2 structure, the dimensions of the
axial pore of the ClpP1 ring (∼30 Å wide) and ClpP2 ring (∼25 Å
wide) were substantially larger than the axial pores of the ClpP1
rings in the ClpP1P1 complex (∼12 Å), although disordered
residues may fill some of the pore in each of these structures
(Fig. 2 C, D, and F).
As described in detail below, the binding of ADEP-2B5Me to the
LGF-pockets of ClpP2, the binding of peptide agonists within the
active sites of ClpP2 and ClpP1, the active-site architecture, and
the overall structure of ClpP1P2were all indicative of a catalytically
competent conformation. The well-structured equatorial interface
in ClpP1P2 also is a feature observed in the active conformations of
homomeric ClpP enzymes (1), although the latter structures have
a symmetric equatorial interface, whereas the interface in ClpP1P2
was asymmetric. Conversely, the symmetric equatorial interface in
the compressed ClpP1P1 tetradecamer was somewhat disordered,
and the active-site architecture and absence of agonist peptides
were consistent with an inactive conformation. Indeed, modeling
Z-Ile-Leu in the conformation observed in the ClpP1-active sites of
ClpP1P2 into the ClpP1P1 structure predicted major steric clashes
with main-chain and side-chain atoms.
Exclusive Binding of ADEP to ClpP2. ADEP-2B5Me occupied the
LGF-binding pockets at each subunit–subunit interface in the
ClpP2 ring (Fig. 2C and Fig. S3A) and bound largely as in other
ADEP•ClpP structures (14, 15). The Ile-like acyl portion of
ADEP-2B5Me filled a groove lined by hydrophobic residues and the
aliphatic portions of the Lys35 and Glu39 side chains of ClpP2,
whereas the difluorophenylalanine ring projected snuggly into a
triangular hydrophobic pocket with a narrow opening (Fig. 3 A–C
and Fig. S3A). As noted above, these interactions likely partially
mimic contacts made by LGF peptides in flexible loops of
M. tuberculosis ClpX and/or ClpC1. The acyl and difluor-
ophenylalanine parts of ADEP-2B5Me made predominantly
hydrophobic interactions with ClpP2, whereas the macrocycle
made numerous polar and apolar contacts that appear to be
stabilized by transannular hydrogen bonds that constrain its
conformation (Fig. 3A).
The presence of ADEP in only the ClpP2 ring suggests that
binding to one ring is sufficient to stabilize an active conformation
of both rings. In support of this model, we found that ADEP-2B
stimulated the peptidase activity of a complex of wild-type ClpP1
and catalytically inactive ClpP2S110A (Fig. S4). This allosteric
effect is in line with the observation that ADEP-2B stimulates
fluorophosphonate modification of both active sites (Fig. 1D).
Higher concentrations of ADEP-2B were needed to activate
ClpP1P2S110A than to activate ClpP1P2, and no activation was ob-
served in ClpP1S98AP2, which has an inactivating catalytic mutation
in ClpP1 (Fig. S4). These observations suggest that the catalytic
Table 1. Data collection and refinement statistics (molecular
replacement)
Parameters
ClpP1P2•ADEP•Z-Ile-Leu
(PDB ID code 4U0G)
ClpP1 (PDB ID
code 4U0H)
Data collection
Space group P212121 P6122
Cell dimensions
a, b, c, Å 154.8, 187.6, 294.0 178.9, 178.9, 265.3
α, β, γ, ° 90, 90, 90 90, 90, 120
Resolution, Å 50 (3.20) 50 (3.25)
Rsym 0.152 (0.550) 0.192 (0.514)
Average I/σI 13.5 (3.6) 12.8 (5.1)
Completeness, % 100 (100) 98.9 (98.7)
Redundancy 6.8 (7.1) 6.0 (6.3)
Refinement
Resolution, Å 3.20 3.25
No. reflections 140,896 39,709
Rwork/Rfree 0.190/0.222 0.180/0.214
No. nonhydrogen atoms
Protein 39,266 9,426
ADEP-2B5Me 798 —
Z-Ile-Leu 756 —
Other ligands 235 70
Water 29 34
β-Factors
Protein 33.2 26.5
ADEP-2B5Me 45.0 —
Z-Ile-Leu 59.2 —
Other ligands 58.2 79.6
Water 15.2 12.8
rmsd
Bond lengths, Å 0.004 0.003
Bond angles, ° 0.705 0.631
Data were collected on a single crystal for each structure. Values in pa-
rentheses represent the highest-resolution shell.
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serine mutations may destabilize active complexes either directly
or indirectly by weakening agonist binding (see below).
Modeling suggested that ADEP does not bind to ClpP1 in
ClpP1P2 because the macrocycle would clash with the ring of
Tyr91, which adopts a rotamer conformation constrained by
stacking interactions with flanking aromatic side chains (Fig. S3 B
and C). The pockets for the acyl and difluorophenylalanine parts
of the ADEP side chain were present in the ClpP1 ring of ClpP1P2
(Fig. S3B) but were eliminated by conformational rearrangements
in the compressed and inactive ClpP1P1 structure, suggesting that
an ADEP side chain might bind to an active ClpP1 ring. Thus,
we tested ClpP1P2 activation by an ADEP-2B fragment (N-E-2-
heptenoyldifluorophenylalanine methyl ester) in which the side
chainwas appended to a small methoxy group rather than the bulky
macrocycle; this fragment activates Bacillus subtilis ClpP and has
antibacterial activity (33). In experiments performed in the pres-
ence of Z-Ile-Leu agonist, the fragment activated peptide cleavage
by ClpP1P2, albeit more weakly and to a lower maximal level than
ADEP-2B (Fig. 3D). Importantly, however, titration of an equi-
molar mixture of the fragment and ADEP-2B increased ClpP1P2
activity to a higher maximal level than ADEP alone (Fig. 3D), an
outcome that would not be expected if both molecules bound only
to the ClpP2 ring. Titration of ADEP-2B in the presence of a sat-
urating amount of fragment (200 μM) resulted in a tighter apparent
ADEP-2B affinity (Fig. 3D), supporting a model in which active
ClpP1P2 can be synergistically stabilized by the binding of the
fragment to ClpP1 and the binding of ADEP-2B to ClpP2.
ADEP Stabilizes Open-Pore Conformations of ClpP2 Directly and of
ClpP1 Indirectly. The N-terminal loops of ClpP2 (N-loops; resi-
dues 19–30) formed an extended annulus of β-hairpins projecting
∼12 Å above the open ClpP2 pore (Fig. 2B). The N-loops of
ADEP-bound Escherichia coliClpP project a shorter distance (15),
have a more polar sequence at their apex, and interact with pore-2
loops from ClpX, helping mediate productive collaboration during
protein degradation (19). These N-loop differences may explain
why E. coli ClpP does not function with M. tuberculosis ClpX or
ClpC1 (23).
Glu21 and Lys28 in the ClpP2 β-hairpin form salt bridges with
Lys35 and Glu38 in helix α1 of the same subunit (Fig. 4). These
interactions and Lys35•••Glu39 and Lys35•••Glu38 salt bridges
link the conformation of the N-loops to packing interactions
between the Ile-like portion of the ADEP acyl side chain and the
nonpolar portions of the Lys35 and Glu39 side chains (Fig. 4),
directly stabilizing the open axial pore of the ClpP2 ring. The
ClpP2 N-loop conformation also was stabilized in the crystal by
interdigitation of N-loops from a ClpP2 ring related by crystal-
lographic symmetry (Fig. S5), which may mimic contacts normally
formed by pore-2 loops from a ClpX or ClpC1 AAA+ partner.
However, no stabilizing interactions were found between the
extended β-hairpins of adjacent N-loops from the same ClpP2
ring, and thus the distal portions of these loops are likely to be
conformationally dynamic in the absence of crystal contacts.
The pore of the ClpP1 ring in ClpP1P2 appeared to be open,
and the ClpP1 N-loops were disordered (Fig. 2D). We cannot
exclude the possibility that the ClpP1 pore is closed by multiple
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Fig. 2. ClpP1P2 and ClpP1P1 structures. (A) Electron-density map (contoured at 1.5 σ) from the ClpP1P2 structure, showing equatorial interactions between
residues 124–148 in a ClpP1 subunit (stick representation; orange carbons) and residues 136–162 in a ClpP2 subunit (stick representation; cyan carbons). (B) Side
view of the ClpP1P2 tetradecamer. The ClpP1 heptamer (orange or red subunits) and ClpP2 heptamer (cyan or blue subunits) are shown in cartoon representation.
Spheres represent ADEP-2B5Me molecules (yellow) bound to the ClpP2 ring and Z-Ile-Leu peptides (green) bound to the active sites of both rings. (C) Axial view of
the ClpP1P2 tetradecamer from the ClpP2 side. (D) Axial view of the ClpP1P2 tetradecamer from the ClpP1 side. (E) Side view of the ClpP1P1 tetradecamer, which
crystallized under the same conditions as ClpP1P2 but did not bind ADEP or Z-Ile-Leu ligands. Note that the structure is wider but shorter than ClpP1P2 (compare
with B). (F) Axial view of the ClpP1P1 tetradecamer. The structural representations and color schemes used in B are also used in C–F.
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conformations of the missing residues, but the “open” pore was
clearly very different from the closed pore of the ClpP1P1 struc-
ture. We note that the sequences of the N-loops of ClpP1 would
not allow them tomake some interactions that stabilize the N-loop
hairpin of ClpP2 and that the ClpP1 pores face large solvent
cavities in both the ClpP1P2 and ClpP1P1 crystals (Fig. S5 C
and D). Thus, it seems unlikely that crystal packing disrupts or-
dered N-loops around the ClpP1 pore. Given that ADEPs bound
only to ClpP2 stabilize an active ClpP1 ring (Fig. 1D and Fig. S4),
allosteric effects also may stabilize an open-pore conformation of
the ClpP1 ring.
Similarities and Differences Between the ClpP1 and ClpP2 Active
Sites. In each subunit of both the ClpP1 and ClpP2 rings, the
Ser-His-Asp catalytic triad and oxyanion hole adopted a catalyti-
cally competent conformation (Fig. 5). Z-Ile-Leu peptides also
were present in each active site of both rings of ClpP1P2. How-
ever, these agonist peptides bound in the reverse orientation from
bona fide peptide substrates, which would pair in an antiparallel
manner with the β9 strand (34). In contrast, Z-Ile-Leu paired with
this strand in a parallel fashion, with the N-terminal carboxy-
benzyl-protecting group (indicated by the Z) occupying the S1
substrate-binding pocket (Fig. 5 and Fig. S6 A and B). Notably, all
peptides known to function as agonists contain an N-terminal
carboxybenzyl group (29). The “reverse” binding orientation also
explains why agonist peptides are not cleaved, because no peptide
bond is positioned for nucleophilic attack by the active-site serine
(Fig. 5). Nevertheless, agonist still would competitively inhibit
binding of an actual substrate. Thus, agonist concentrations suf-
ficient to bind many (but not all) of the 14 active sites can activate
ClpP1P2 cleavage of peptide substrates, but very high agonist
concentrations inhibit peptide cleavage (29).
ClpP1P2 variants with active-site mutations in one ring or the
other have distinct substrate specificities, and the ClpP2 ring
reacts preferentially with mechanism-based β-lactone inhibitors
(29, 35). These observations can be explained by differences in
the substrate-binding clefts of ClpP1 and ClpP2, which also af-
fect Z-Ile-Leu binding. ClpP1 has a deep S1 pocket and a longer
strand β9, which formsmultiple hydrogen bonds with the backbone
of the agonist peptide (Fig. 5A and Fig. S6A). In the structure, all
Z-Ile-Leu molecules that bind to the active sites of ClpP1 adopted
the same conformation with clear electron density for the entire
peptide. In ClpP2, in contrast, a shallower S1 pocket and a shorter
strand β9 terminated by a “bulge” (residues 139–143) resulted in
a somewhat different Z-Ile-Leu conformation (Fig. 5B and Fig.
S6B). For example, the bulge created a different binding site for
the Ile side chain of the agonist, which packed against the side
chain of Leu139. The electron density for Z-Ile-Leu molecules
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Fig. 3. ADEP binding to ClpP2. (A) ADEP-2B5Me (stick representation; yellow carbons) binds in a pocket between adjacent ClpP2 subunits (ribbon repre-
sentation; one subunit is blue, and one is cyan). Selected side chains of ClpP2 are shown in stick representation. Dashed lines represent hydrogen bonds. The
ADEP difluorophenylalanine side chain packs against Leu61, Tyr75, Tyr95, Leu105, and Leu127; the ADEP acyl side chain packs against Leu36, Ile41, Leu61,
Tyr75, and the aliphatic portions of Lys35 and Glu39; and the ADEP macrocycle makes hydrophobic interactions with Val103, Met125, and Leu204 and hy-
drogen bonds with Tyr75, Tyr95, and Arg97. (B) The acyl side chain of ADEP-2B5Me lies in a hydrophobic groove on the surface of the ClpP2 ring. (C) The
difluorophenylalanine side chain of ADEP-2B5Me projects into a deep hydrophobic pocket in the ClpP2 ring. (D) Vmax for ClpP1P2 decapeptide cleavage was
0.02 peptide·min−1·ClpP1P2−1 in the presence of saturating ADEP-2B side-chain fragment (N-E-2-heptenoyldifluorophenylalanine methyl ester; structure
shown; red curve), 0.13 peptide·min−1·ClpP1P2−1 for ADEP-2B (blue curve), and 0.18 peptide·min−1·ClpP1P2−1 for an equimolar mixture of ADEP-2B and
fragment (dashed purple curve). ADEP-2B binding in the presence of the 200-μM fragment (solid purple curve) was tighter (Kapp = 7.9 ± 0.2 μM) and less
cooperative (Hill constant = 1.2 ± 0.03) than in its absence (Kapp = 16 ± 0.04 μM; Hill constant = 1.5 ± 0.05). In addition to ADEP and/or fragment, reactions
contained ClpP1 and ClpP2 (0.25 μM each), decapeptide (15 μM), and Z-Leu-Leu-Nva-CHO peptide (50 μM). Values are averages ± SD (n = 3). Lines are fits to
a Hill equation; fitted parameters are listed in Table S1.
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bound to ClpP2 was strongest for the Z-Ile segment but was
weaker at the C terminus (Fig. S1E), suggesting multiple con-
formations of the terminal Leu residue.
Interestingly, small channels were present near the active sites in
the ClpP1 ring of ClpP1P2 (Figs. S5A and S7). In a few instances,
electron density suggested that these channels were occupied
partially by peptides, presumably additional molecules of Z-Ile-
Leu. Although the large axial pores are likely to be the main con-
duits for substrate entry and product egress from the degradation
chamber of ADEP-/agonist-stabilized ClpP1P2, the ClpP1 chan-
nels might play accessory roles in egress, especially in complexes of
ClpP1P2 with ClpX and/or ClpC1.
Structural Basis of Homomeric-Ring Specificity and Heteromeric
Tetradecamer Formation. Why are mixtures of ClpP1 and ClpP2
subunits not found in a single heptameric ring? Although many of
the lateral interactions between subunits are similar in each ring,
several unique interactions stabilize discrete ClpP1 or ClpP2
homoheptamers. In ClpP1, for example, the side chain of His117
forms salt bridges with the side chains of Asp79 and Glu149 in an
adjacent ClpP1 subunit, as part of an extended polar network (Fig.
6A). ClpP2 lacks this histidine and cannot make analogous inter-
actions with ClpP1. In ClpP2, the side chains of Tyr206, Arg207,
and Lys208 in a structured C-terminal region make polar and
packing interactions with residues in helix αC of an adjacent ClpP2
subunit (Fig. 6B). These residues are not conserved in ClpP1, and
the corresponding C-terminal region of ClpP1 is disordered in both
the ClpP1P2 and ClpP1P1 crystal structures.
In contrast, residues in the “handle” regions (αE and β9) that
form the equatorial interface favor heteromeric association be-
tween a ClpP1 heptamer and a ClpP2 heptamer. In ClpP2, for
example, the aromatic ring of Phe147, a residue located at the
beginning of helix αE and the apex of the handle, projects into a
hydrophobic pocket at the base of the ClpP1 handle, between αE
and β9 (Fig. 6 C and D). Phe147 in ClpP2 is replaced by Ala133 in
ClpP1. Thus, a homomeric ClpP1 tetradecamer would lack this
stabilizing interaction. Although ClpP2 has a corresponding
hydrophobic pocket at the base of its handle region, this pocket is
unlikely to accommodate Phe147 from another ClpP2 ring, because
modeling a ClpP2P2 tetradecamer based on ClpP1P2 predicted
severe clashes between the two β9-buldge regions (Fig. S8). Rear-
ranging these regions might permit interactions between ClpP2
rings but probably would collapse the adjacent substrate-binding
pocket, distort the catalytic triad, and inactivate the enzyme.
Discussion
The ClpP1P2 structure provides a foundation for understanding
the unusual properties of Clp-family proteases in M. tuberculosis.
For example, the joint requirement of ClpP1 and ClpP2 for pep-
tidase or protease activity (23, 29) is explained by the asymmetric
but complementary equatorial interface between aClpP1 heptamer
and a ClpP2 heptamer in ClpP1P2. Symmetric interactions be-
tween either single ring are possible, as observed directly in the
ClpP1P1 structure, but result in inactive tetradecamers with col-
lapsed or occludedLGF-binding pockets and substrate-binding clefts.
This work provides insight into small-molecule stabilization of
ClpP enzymes that do not form stable or active tetradecamers in
isolation. Agonist and ADEP binding to ClpP1P2 were expected
to mimic the binding of polypeptide substrates and AAA+ part-
ners, respectively (14, 15, 20, 21, 23, 29). For both activating
ligands, however, surprises emerged. For example, the Z-Ile-Leu
agonist bound in a completely different orientation than an actual
substrate. Despite this difference in orientation, agonists have
activating effects similar to those of polypeptide substrates de-
livered by a AAA+ partner. In another surprise, ADEPs bound
exclusively to the LGF-binding pockets of the ClpP2 ring but
stabilized open axial pores and catalytically competent active-site
conformations in both rings. Collectively, these observations
Phe25
Ile15
Glu38Glu21
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Lys28
Pro17
Phe19
Lys35
Fig. 4. The N-loops of ClpP2 (residues 19–30; cartoon and stick represen-
tation; cyan) adopt an extended β-hairpin that is stabilized by salt bridges
(dashed lines) and packing between the acyl chain of an ADEP-2B5Me mol-
ecule (stick and sphere representation; yellow) and the nonpolar portions of
the Lys35 and Glu39 side chains.
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Leu139
Fig. 5. Peptide agonists bind to the active sites of ClpP1 and ClpP2 in an
orientation opposite that of peptide substrates. (A) Structure of the Z-Ile-Leu
peptide (stick representation; green carbons) bound to the active site of
ClpP1 (stick representation; most carbons are dark red; catalytic-triad carbons
are white; small spheres mark oxyanion-hole NH groups). The N-terminal
carboxybenzyl or Z blocking group occupies the S1 pocket, where the P1
residue of a substrate (on the C-terminal side of the scissile peptide bond)
normally would bind. The backbone of the Z-Ile-Leu peptide forms a parallel
β-sheet with strand β9, whereas a peptide substrate would bind in an anti-
parallel manner. (B) Binding of Z-Ile-Leu to the active site of ClpP2 (stick
representation; most carbons are blue; catalytic-triad carbons are white; small
spheres mark oxyanion-hole NH groups). A five-residue bulge, following
a shorter β9, results in the side chains of the Z-Ile-Leu peptide making different
interactions with ClpP2 than with ClpP1.
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indicate that the conformations of the LGF-binding pockets,
axial pores, and active sites in both rings of ClpP1P2 must be
tightly and allosterically coupled. The synergy of ADEPs and
agonists in activating ClpP1P2 indicates that both molecules bind
preferentially to functional ClpP1P2 and thus stabilize this species
relative to any inactive conformations.
There is substantial evidence that ADEP toxicity results from
a gain-of-function mechanism in which the open axial pores of
ADEP-bound ClpP allow entry and degradation of unfolded or
misfolded proteins (14, 15, 20, 21). Because we find that ADEPs
both open the pores and activate M. tuberculosis ClpP1P2, it is
plausible that rogue degradation of cellular proteins is also re-
sponsible for ADEP killing ofM. tuberculosis (30). However, given
that theM. tuberculosis clpX and clpC1 genes are essential (26–28),
it also is possible that a loss-of-function mechanism contributes to
ADEP killing. Specifically, ADEP disruption of the interaction
between ClpP1P2 and an accessory AAA+ partner could lead to
the accumulation of toxic proteins that are normally substrates of
these Clp proteases (2). Indeed, in support of this possibility, our
results clearly show that ADEPs inhibit protein degradation by
ClpX•ClpP1P2.
An unusual feature of the ClpP1P2 system is the requirement
for activators (23, 29). A mixture of ClpP1 and ClpP2 has very
low peptidase activity and probably consists of a small concen-
tration of active ClpP1P2 tetradecamers and much higher con-
centrations of numerous inactive species (heptamers of ClpP1
and ClpP2; tetradecamers of ClpP1P1, ClpP2P2, and possibly an
inactive conformation of ClpP1P2). By binding more tightly to
the subpopulation of active ClpP1P2 enzymes than to inactive
molecules, ClpX, ClpC1, and the protein substrates they deliver
shift the equilibrium toward this active species. This design
couples ClpP1P2 activity to AAA+ partner activity, perhaps as
a way to protect the cell from degradation by ClpP1P2 during
periods of low metabolic activity when ATP and protein sub-
strates are likely to be scarce (23).
The existence of discreteM. tuberculosis ClpP1 and ClpP2 rings
might allow specialization compared with homomeric ClpPs, in
which each ring normally can interact with several AAA+ part-
ners (36). For example, structural differences between the LGF-
binding pockets and N-loops of the ClpP1 and ClpP2 rings could
result in ClpX binding to one ring and ClpC1 to the other ring,
perhaps as a way to balance the degradation of substrates rec-
ognized by each AAA+ partner. Although the specificity of AAA+
partner binding to ClpP1P2 might be probed by mutating or per-
turbing one ring or the other, allosteric coupling complicates this
approach. For instance, ADEP binds exclusively to the ClpP2 ring
and inhibits ClpX•ClpP1P2 degradation, but this result could be
explained by direct competition (ClpX binds ClpP2) and/or by an
allosteric model (ClpX binds ClpP1). The detailed basis of het-
eromeric ClpP1P2 architecture reported here suggests an alter-
native approach for probing functional interactions with AAA+
partners, namely structure-based engineering of ClpP1 or ClpP2
variants in which mutations in the handle regions allow symmetric
interfaces compatible with peptidase function and thus assembly
of homomeric tetradecamers.
The ClpP1P2 structure and biochemical studies highlight the
need for synergistic activation by two factors. For example, robust
activation of ClpP1P2 in vitro requires a AAA+ partner and
substrate delivery (23), a AAA+ partner and agonist peptide (29),
or an ADEP and agonist peptide, as we have shown here. The
assembly state of ClpP1P2 in vivo, and thus its sensitivity to
hyperactivation and/or active-site inhibition, is not known. It
seems likely, however, that physiological conditions that lead to
very slow growth or metabolic inactivity also would render most
ClpP1P2 resistant to inhibition or dysregulation. Under these
conditions, a mixture of ADEPs and agonists could be more
effective than ADEPs alone in killing M. tuberculosis and might
sensitize the pathogen to killing by β-lactones (35) or other
active-site inhibitors. The ClpP1P2 structure reported here also
should aid in the design of new and more potent ADEPs and/or
ADEP fragments that target both rings. Efforts toward this goal
are underway.
Methods
Proteins and Small Molecules. Mature M. tuberculosis ClpP1 (resi-
dues 7–200) and ClpP2 (residues 13–214) with C-terminal His6-tags
were expressed and purified as described (35). For active-site la-
beling experiments, a SUMO domain was cloned between ClpP1
and the C-terminal His6-tag, and the protein was purified in the
same manner as ClpP1. For crystallography, ClpP1 labeled with
selenomethionine was prepared by growing a strain containing
a plasmid overexpressing ClpP1 in Luria–Bertani medium con-
taining 100 mg/L L-selenomethionine for 5 h at room tempera-
ture and was purified as described (35). M. tuberculosis ClpX
fused to an N-terminal His7-SUMO domain to enhance solubility
and H6-GFP with a C-terminal ADSHQRDYALAA sequence
corresponding to the M. tuberculosis ssrA tag (GFP-ssrA) were
expressed and purified as described (23). ClpP concentrations are
reported in tetradecamer equivalents. Z-Ile-Leu was purchased
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Fig. 6. Interactions that provide specificity within and between heptameric
rings in ClpP1P2. (A) The side chain of His147 from one ClpP1 subunit (orange)
is an integral part of a salt-bridge network that includes the side chains of
Asp79, Glu149, Arg152, and Glu156 from a second ClpP1 subunit (red). (B)
Residues 206–208 in the ordered C-terminal region of one ClpP2 subunit (cyan)
interact with residues 91–95 in an adjacent ClpP2 subunit (blue). The side-chain
hydroxyl of Tyr206 makes a hydrogen bond with Asp91; the aliphatic portion
of the Arg207 side chain packs against the Tyr95 ring; and the side chain of
Lys208 projects into a cleft with the side chain amine making a hydrogen bond
with the carbonyl oxygen of Met93. (C and D) Asymmetric interface between
the handle regions of ClpP1 (red and orange) and ClpP2 (blue and cyan).
Phe147, at the tip of the ClpP2 handle, projects into a pocket at the base of the
ClpP1 handle, whereas the symmetric Ala133 side chain in ClpP1 makes no
comparable interaction. Strand β9 in ClpP2 is terminated by a bulge that
projects inward and forms part of the substrate binding site (see Fig. 5B).
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from Sigma. Z-Leu-Leu-Nva-CHO was purchased from Boston
Biochem. ADEPs and N-E-2-heptenoyldifluorophenylalanine
methyl ester were synthesized as described (30, 31, 33, 37).
Enzymatic Assays. Assays were performed at 30 °C in a SpectraMax
M5 microplate reader (Molecular Devices) in protein degradation
(PD) buffer [25 mMHepes, 100 mMKCl, 5 mMMgCl2, 10% (vol/
vol) glycerol, 5% (vol/vol) DMSO, 1 mM DTT, 0.1 mM EDTA,
0.1% Tween-20, pH 7.5]. Degradation of the fluorogenic Abz-
KASPVSLGYNO2D decapeptide (12) was followed by increases in
fluorescence (excitation, 320 nm; emission, 420 nm). GFP-ssrA
degradation was assayed by decreases in fluorescence (excita-
tion, 380 nm; emission, 511 nm) in the presence of 2.5 mM ATP
(Sigma) and a regeneration system consisting of 16 mM creatine
phosphate (MP Biomedicals) and 0.32 mg/mL creatine phos-
phokinase (Sigma).
Active-Site Labeling.ClpP1P2 (0.5 μM) was incubated with TAMRA-
fluorophosphonate (2 μM; Thermo Pierce) with or without ADEP-
2B (50 μM) and/or Z-Ile-Leu (0.5 mM) in PD buffer at 30 °C.
Reactions were quenched at different times by addition of SDS/
PAGE loading buffer, frozen at –20 °C, and subjected to SDS/
PAGE, and TAMRA fluorescence was detected using a Typhoon
FLA 9500 imager (GE Healthcare Life Sciences).
Crystallization and Structure Determination. Hanging drops con-
sisting of 0.6 μL protein [2.5 mg/mL selenomethionine-labeled
ClpP1, 2.5 mg/mL ClpP2, 0.2 mM ADEP-2B5Me, 0.5 mM Z-Ile-
Leu, 10 mM Hepes, 50 mM NaCl, 0.5 mM TCEP, 15% (vol/vol)
DMSO, pH 7.5] and 0.6 μL precipitant [1.5 M (NH4)2SO4, 0.1 M
MES, pH 6.5] were suspended over a reservoir of 500 μL of
precipitant and incubated at 20 °C. Rod-shaped hexagonal
crystals (50 × 50 × 200 μm) and rectangular crystals (100 × 100 ×
200 μm) formed over a period of ∼9 mo. Crystals were soaked
briefly in cryoprotection solution (1.9 M Li2SO4, 50 mM MES,
pH 6.5) and flash frozen in liquid N2.
X-ray diffraction data were collected at the Advanced Photon
Source (APS) beamlines 24-ID-C (ClpP1P1) and 24-ID-E
(ClpP1P2) at 100 K and with X-ray wavelengths near the Se edge
(0.9790 Å for ClpP1P1; 0.9792 Å for ClpP1P2). Raw data were
processed using HKL2000 (38). The ClpP1P1 structure was solved
by molecular replacement with Phaser (39) as implemented in
CCP4 (40) using the ClpP1 structure [Protein Data Bank (PDB)
ID code 2CE3] as a search model (32). The ClpP1P2 structure was
solved by molecular replacement using search models for a ClpP1
heptamer (PDB ID code 2CE3) (32) and a ClpP2 heptamermodel
based on E. coliClpP (PDB ID code 1TYF) (9). Models were built
with Coot (41) and refined using Phenix (42), with torsion-based
noncrystallographic restraints for identical chains in the asym-
metric unit. The percentage of residues with favored/allowed/dis-
allowed Ramachandran dihedral angles was 97.7/2.3/0 for the
ClpP1P1 structure and 98.6/1.4/0 for the ClpP1P2 structure.
Coordinates for both structures have been deposited in the Protein
Data Bank with ID codes 4U0G (ClpP1P2) and 4U0H (ClpP1).
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